Tianda Pharmaceuticals Ltd. (HK:0455)
:0455
0455 Stock Chart & Stats
HK$0.13
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$0.13
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$0.07 - HK$0.22
Previous CloseN/A
Volume4.00K
Average Volume (3M)84.94K
Market Cap
HK$208.55M
Enterprise ValueHK$276.40M
Total Cash (Recent Filing)HK$103.77M
Total Debt (Recent Filing)HK$98.81M
Price to Earnings (P/E)―
Beta0.37
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,150,041,700
10 Day Avg. Volume115,400
30 Day Avg. Volume84,945
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)0.72
Price to Sales (P/S)1.10
P/FCF Ratio-6.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Revenue StreamsTianda's revenue model spans prescription drugs, OTC products and traditional Chinese medicine plus licensing and distribution partnerships. This diversification reduces dependence on a single product or channel, supporting steadier demand and resilience across healthcare segments over months.
Manageable LeverageA moderate debt-to-equity ratio (0.25) indicates limited financial leverage, lowering interest burden and preserving capacity to fund R&D or working capital. This balance sheet conservatism supports financial flexibility and reduces refinancing risk over a multi-month horizon.
Improving Free Cash Flow GrowthReported improvement in free cash flow growth signals that management may be extracting more cash from operations or capital efficiency gains. If sustained, better free cash flow improves liquidity and reduces reliance on external funding for investment or debt service.
Bears Say
Declining RevenueA sharp revenue decline (-14.23%) erodes scale and bargaining power, squeezing gross margins and reducing funds available for R&D, marketing and commercialization. Continued top-line contraction would undermine long-term competitiveness and investment capacity.
Ongoing Losses And Negative Operating Cash FlowSustained net losses and negative operating cash flow deplete equity and constrain operational flexibility. Over time this can force asset sales, dilution, or increased borrowing, limiting the company's ability to invest in drug development or expand commercial efforts.
Negative Return On EquityA negative ROE indicates the company is destroying shareholder capital, reflecting unprofitable operations and weak margins. Persisting negative ROE reduces investor confidence and hampers the firm's ability to attract equity financing for long-term growth initiatives.
Tianda Pharmaceuticals Ltd. News
0455 FAQ
What was Tianda Pharmaceuticals Ltd.’s price range in the past 12 months?
Tianda Pharmaceuticals Ltd. lowest stock price was HK$0.07 and its highest was HK$0.21 in the past 12 months.
What is Tianda Pharmaceuticals Ltd.’s market cap?
Tianda Pharmaceuticals Ltd.’s market cap is HK$208.55M.
When is Tianda Pharmaceuticals Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Tianda Pharmaceuticals Ltd.’s earnings last quarter?
Currently, no data Available
Is Tianda Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Tianda Pharmaceuticals Ltd.’s price is currently Overvalued.
Does Tianda Pharmaceuticals Ltd. pay dividends?
Tianda Pharmaceuticals Ltd. does not currently pay dividends.
What is Tianda Pharmaceuticals Ltd.’s EPS estimate?
Tianda Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tianda Pharmaceuticals Ltd. have?
Tianda Pharmaceuticals Ltd. has 2,150,041,700 shares outstanding.
What happened to Tianda Pharmaceuticals Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Tianda Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in HK:0455
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tianda Pharmaceuticals Ltd.
Tianda Pharmaceuticals Limited, an investment holding company, engages in the research and development, production, and sale of pharmaceutical, biotechnology, and healthcare products in Mainland China, Hong Kong, and Australia. Its product range includes Chinese medicines, chemical drugs, biological and health products, and medical appliances covering the area of cardio-cerebrovascular, pediatric, anti-flu and respiratory, anti-infection, detoxification, urological agents, and others. The company offers its health products under the Herb Valley and Tuokang brands. It also engages in the sale and wholesale of Chinese herbal medicines, traditional Chinese medicine decoction pieces and Chinese medicines; provision of Chinese medical services; and trading of agricultural by-products. The company was formerly known as Tianda Holdings Limited and changed its name to Tianda Pharmaceuticals Limited in September 2012. The company was incorporated in 1992 and is headquartered in Central, Hong Kong. Tianda Pharmaceuticals Limited is a subsidiary of Tianda Group Limited.
Technical Analysis
Wai Yuen Tong Medicine Holdings Limited
―
China NT Pharma Group Co., Ltd.
―
Fusen Pharmaceutical Co., Ltd.
―
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H
―
Huakang Biomedical Holdings Company Limited
―